These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 25597501)

  • 1. Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?
    Bozza C; Fontanella C; Buoro V; Mansutti M; Aprile G
    Expert Rev Clin Pharmacol; 2015 Mar; 8(2):251-65. PubMed ID: 25597501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast tumour angiogenesis.
    Fox SB; Generali DG; Harris AL
    Breast Cancer Res; 2007; 9(6):216. PubMed ID: 18190723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab for advanced breast cancer.
    Traina TA; Rugo HS; Dickler M
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):303-19. PubMed ID: 17512451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting angiogenesis in advanced breast cancer.
    Zelnak AB; O'Regan RM
    BioDrugs; 2007; 21(4):209-14. PubMed ID: 17628118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic agents in breast cancer.
    Salter JT; Miller KD
    Cancer Invest; 2007 Oct; 25(7):518-26. PubMed ID: 18027149
    [No Abstract]   [Full Text] [Related]  

  • 6. A Combinatorial Investigation of the Response to Anti-angiogenic Therapy in Breast Cancer: New Strategies for Patient Selection and Opportunities for Reconsidering Anti-VEGF, Anti-PI3K and Checkpoint Inhibition.
    Labanca V; Bertolini F
    EBioMedicine; 2016 Aug; 10():13-4. PubMed ID: 27506898
    [No Abstract]   [Full Text] [Related]  

  • 7. Antiangiogenic strategies in breast cancer management.
    Giovannini M; Aldrighetti D; Zucchinelli P; Belli C; Villa E
    Crit Rev Oncol Hematol; 2010 Oct; 76(1):13-35. PubMed ID: 20702105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Angiogenesis and breast cancer].
    Bachelot T; Ray-Coquard I; Cassier P; Blay JY
    Bull Cancer; 2007 Jul; 94 Spec No():S203-10. PubMed ID: 17846006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug insight: VEGF as a therapeutic target for breast cancer.
    Schneider BP; Sledge GW
    Nat Clin Pract Oncol; 2007 Mar; 4(3):181-9. PubMed ID: 17327858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current overview of angiogenesis inhibitors.
    Ellis LM
    Clin Adv Hematol Oncol; 2004 Aug; 2(8):494-6, 520. PubMed ID: 16163228
    [No Abstract]   [Full Text] [Related]  

  • 12. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
    Cao Y; Liu Q
    Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapies in breast cancer.
    Sarmiento R; D'Andrea MR; Cacciamani F; Salerno F; Gasparini G
    Curr Opin Investig Drugs; 2009 Dec; 10(12):1334-45. PubMed ID: 19943205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
    Wilson PM; LaBonte MJ; Lenz HJ
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis as a strategic target for ovarian cancer therapy.
    Spannuth WA; Sood AK; Coleman RL
    Nat Clin Pract Oncol; 2008 Apr; 5(4):194-204. PubMed ID: 18268546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcitriol reduces thrombospondin-1 and increases vascular endothelial growth factor in breast cancer cells: implications for tumor angiogenesis.
    García-Quiroz J; Rivas-Suárez M; García-Becerra R; Barrera D; Martínez-Reza I; Ordaz-Rosado D; Santos-Martinez N; Villanueva O; Santos-Cuevas CL; Avila E; Gamboa-Domínguez A; Halhali A; Larrea F; Díaz L
    J Steroid Biochem Mol Biol; 2014 Oct; 144 Pt A():215-22. PubMed ID: 24120914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis in Colorectal Cancer: Antibodies.
    Chan E
    Cancer J; 2016; 22(3):179-81. PubMed ID: 27341595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential of anti-vascular endothelial growth factor therapy in metastatic breast cancer: clinical experience with anti-angiogenic agents, focusing on bevacizumab.
    Marty M; Pivot X
    Eur J Cancer; 2008 May; 44(7):912-20. PubMed ID: 18396037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.